The NEO3-06 trial comparing lymphoseek to radical ALND in Head & Neck cancers will be a very interesting study imho. I think enrollment for Head & Neck is currently at 190 patients, so I suspect the interim analysis is near.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.